Join the Baricitinib group to help and get support from people like you.
Baricitinib News
AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
TUESDAY, March 18, 2025 – For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health professionals, and others interested i...
Could Olumiant Be A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
FRIDAY, Dec. 20, 2024 – An existing drug might be able to treat an autoimmune disorder that causes dry eye, dry mouth, fatigue and muscle or joint pain. Baricitinib (Olumiant), a drug currently used...
FDA Approves Lilly and Incyte's Olumiant (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata
INDIANAPOLIS, June 13, 2022 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved Olumiant...
FDA Approves Olumiant (baricitinib) Treatment for COVID-19 in Certain Hospitalized Adults
Olumiant is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support INDIANAPOLIS, May 11, 2022...
FDA Medwatch Alert: FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions
This information is an update to the FDA Drug Safety Communication issued on February 4, 2021. FDA also previously communicated about the safety clinical trial with Xeljanz, Xeljanz XR (tofacitinib)...
FDA Approves Olumiant (baricitinib) 2 mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, June 1, 2018 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the...
Further information
Related condition support groups
Alopecia, Rheumatoid Arthritis, COVID-19